A5008714150- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Valve Diseases and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac Imaging and Diagnostics
- Lipoproteins and Cardiovascular Health
- Venous Thromboembolism Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Peripheral Artery Disease Management
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Cardiovascular Disease and Adiposity
- Workplace Health and Well-being
- Cerebrovascular and Carotid Artery Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Health and Mental Health
- Diabetes Treatment and Management
- Sleep and Work-Related Fatigue
- Aortic aneurysm repair treatments
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Acute Kidney Injury Research
- Cardiovascular Issues in Pregnancy
- Medication Adherence and Compliance
Icahn School of Medicine at Mount Sinai
2016-2025
Mount Sinai Hospital
2016-2025
Cardiovascular Institute of the South
2016-2025
Mount Sinai Hospital
2015-2024
Mount Sinai Medical Center
2013-2024
Mount Sinai Health System
2021-2023
Epatocentro Ticino
2023
Amsterdam University Medical Centers
2023
University of Amsterdam
2023
Clinica Mediterranea
2021
Monotherapy with a P2Y12 inhibitor after minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk bleeding percutaneous coronary intervention (PCI).
Relative risk reduction with statin therapy has been consistent across nearly all subgroups studied to date. However, in analyses of 2 randomized controlled primary prevention trials (ASCOT [Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm] and JUPITER [Justification for the Use Statins Prevention: An Intervention Trial Evaluating Rosuvastatin]), led a greater relative among subgroup at high genetic risk. Here, we aimed confirm this observation third trial. In addition, assessed...
Abstract Aims The aim of this study was to determine the effect ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation clinical presentation with without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous intervention (PCI) drug-eluting stents (DES). Methods results We conducted a pre-specified subgroup analysis Ticagrelor With Aspirin or Alone High Risk Patients After Coronary Intervention (TWILIGHT) trial,...
SGLT2i (sodium-glucose cotransporter-2 inhibitors) improve clinical outcomes in patients with heart failure, but the mechanisms of action are not completely understood. increases circulating levels ketone bodies, which has been demonstrated to enhance myocardial energetics and induce reverse ventricular remodeling. However, role or bodies on ischemia reperfusion injury remains dark. The objective this study is investigate cardioprotective potential empagliflozin during acute infarction...
Transcatheter aortic valve replacement (TAVR) harbors the risk of periprocedural complications that require emergent cardiac surgery, or "surgical bailout." Surgical bailout intends to be lifesaving but is associated with high mortality. This has given rise discussion on necessity surgical backup during TAVR. Therefore, recent studies in contemporary TAVR patients are warranted. study aimed assess incidence, trends, and clinical outcomes undergoing transfemoral The CENTER2 (Cerebrovascular...
Abstract Aims Accurate selection of patients with severe heart failure (HF) who might benefit from advanced therapies is crucial. The present study investigates the performance available risk scores aimed at predicting mortality in HF. Methods and results 1‐year was estimated HF enrolled HELP‐HF cohort according to MAGGIC, 3‐CHF, ADHF/NT‐proBNP, GWTG‐HF scores, number criteria 2018 HFA‐ESC definition HF, I NEED HELP markers, domains fulfilled 2019 frailty, frailty index, INTERMACS profile....
Flexible working hours can have several meanings and be arranged in a number of ways to suit the worker and/or employer. Two aspects “flexible” arrangement were considered: one more subjected company control decision (variability) connected individual discretion autonomy (flexibility). The aim study was analyze these two dimensions relation health well‐being, taking into consideration interaction with some relevant background variables related demographics plus social conditions. dataset...
Objective: To report health outcomes of 30 years (1978–2007) medical surveillance workers engaged in a perfluooctanoic acid (PFOA) production plant. Methods: Fifty-three males (20 to 63 years) were submitted every year examination and blood chemical chemistry tests, serum PFOA dosage. Results: In the latest survey levels ranged from 0.20 47.04 μg/mL currently exposed workers, 0.53 18.66 those formerly exposed. No clinical evidence any specific trouble or disease has been recorded over years,...
The project brought together researchers from 9 EU-Countries and resulted in a number of actions, particular the following: (a) There is an urgent need defining concept flexible working hours, since it has been used many different even counterintuitive ways; most obvious distinction where influence over hours lies, that between "company-based flexibility" "individual-oriented flexibility"; (b) review Legislation force 15 European countries shows regulation times quite extensive covers...
The current paper reports the main results of several studies carried out on Italian workers using work ability index as a complementary tool for workers' periodical health surveillance. shows general decreasing trend over years, but it changes differently according to working conditions and personal status. In jobs with higher mental involvement autonomy, lower physical constraint, remains quite constant high while significantly decreases steeper load job control are. Sex hours appear act...
From February 1983 to January 1985, 497 patients with advanced breast cancer were randomly allocated receive either epirubicin or doxorubicin in the following combination chemotherapy regimen: fluorouracil (5-FU) 500 mg/m2 intravenous (IV) on days 1 and 8; 50 IV day 1; cyclophosphamide (FEC FAC). Cycles repeated every 21 until progression cumulative doses of 700 for 550 doxorubicin. Dose reductions applied according standard criteria. Activity was evaluated 443 (222 FEC arm 221 FAC arm). The...
Prediction of cardiovascular events improves using imaging, i.e. coronary calcium score and ultrasound assessment carotid plaque. This study analysed the predictive value two measures plaque size: thickness intima-media (IMT).